Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05290363

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis

Led by Institut Pasteur · Updated on 2025-01-23

90

Participants Needed

4

Research Sites

N/A

Total Duration

On this page

Sponsors

I

Institut Pasteur

Lead Sponsor

J

Janssen Biotech, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating the role of IL-23 in the development and progression of axial and peripheral spondyloarthritis (SpA), including psoriatic arthritis, to better understand how the body responds to anti-IL-23 biologic treatments. This multicenter, non-randomized prospective study focuses on patients attending rheumatology departments in several hospitals and aims to explore the cellular and molecular targets of IL-23 signaling in these chronic inflammatory diseases. Participants are divided into two groups: those with axial SpA and those with peripheral SpA or psoriatic arthritis. The study involves collecting blood samples and, when required as part of standard care, synovial fluid from joint aspirations in peripheral SpA patients. These samples will be used to analyze gene expression, immune cell characteristics, and cytokine production related to IL-23 and IL-17 pathways over a period of up to four years. Throughout the study, participants will undergo assessments including profiling of chromatin regions, transcriptome and genome analysis, cytokine expression monitoring, and single cell transcriptome analysis. The research will also measure lymphocyte levels to observe immune responses to anti-IL-23 treatments. Participants' involvement includes laboratory tests and sample collections aligned with routine care, with the study concluding by September 2027.

CONDITIONS

Brief Title

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults over 18 years old
  • Diagnosed with spondyloarthritis according to ASAS criteria
  • Have active disease with synovitis, tendinitis, dactylitis, or significant inflammatory spinal pain
  • Have signed informed consent
  • Covered by health insurance except AME beneficiaries
  • For Group 1: Patient is new to biological therapies
  • For Group 2: Patient has peripheral SpA or psoriatic arthritis with joint inflammation
  • For Group 2: Patient requires synovial fluid aspiration as part of standard care
Not Eligible

You will not qualify if you...

  • Under 18 years old
  • Pregnant or breastfeeding
  • Immunocompromised
  • Received two or more biological therapies
  • Taking corticosteroids over 10 mg per day
  • Under legal protection such as guardianship or curatorship
  • Refuses consent
  • History of alcoholism, drug addiction, psychological problems, or severe conditions affecting consent or compliance
  • Beneficiary of AME
  • For Group 1: Has received biological therapy before

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Sample Collection

Duration - Up to 4 years

Participants provide blood samples and, if applicable, synovial fluid samples collected during routine care for study analysis.

Visits coincide with routine clinical procedures; synovial fluid collection occurs only if required by standard care

Trial Site Locations

Total: 4 locations

1

Hôpital Henri-Mondor, AP-HP - Service de Rhumatologie

Créteil, France, 94000

Not Yet Recruiting

2

Hôpital Cochin, AP-HP - Department of Dermatology B

Paris, France

Actively Recruiting

3

Hôpital Saint-Antoine, AP-HP - Service de Rhumatologie

Paris, France

Actively Recruiting

4

Hôpital Maison Blanche - Service de Rhumatologie

Reims, France, 51092

Not Yet Recruiting

Loading map...

Research Team

L

Lars ROGGE, Dr

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Similar Trials

The SPARK Trial: A Digital Exercise Intervention for Patient...

Spondyloarthritis

Actively Recruiting

1 location

MEDIBIOTE 3: Analysis of Intestinal Microbiota as a Predicto...

Spondyloarthritis

Actively Recruiting

1 location

Biobank for Inflammatory Chronic Diseases and Osteoporosis o...

Rheumatoid Arthritis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here